Literature DB >> 1832950

Expression of CD45 isoforms by fresh and activated human gamma delta T lymphocytes and natural killer cells.

E Braakman1, E Sturm, K Vijverberg, B A van Krimpen, J W Gratama, R L Bolhuis.   

Abstract

Naive and primed alpha beta T cells can be distinguished on the basis of their differential expression of CD45RA and CD45RO, respectively. The present study indicates that these CD45-isoforms also identify naive and primed maturational stages of gamma delta T cells and natural killer (NK) cells. In peripheral blood, all V gamma 9-V delta 2 gamma delta T cells reportedly express CD45RO whereas all V delta gamma delta T cells lack CD45RO. Here, we show that these CD45RO- V delta gamma delta T cells all express CD45RA and the CD45RO+ V.9-V delta 2 gamma delta cells lack expression of CD45RA. The V delta T cells acquired CD45RO expression and lost part of their surface CD45RA, following in vitro activation with phytohaemagglutinin or IL-2. Also the CD3-CD16+ NK cells in peripheral blood that are uniformly CD45RA+ CD45RO- completely converted to the CD45RA-CD45RO+ phenotype upon in vitro activation. Moreover, all cloned V.9-V delta 2 and V delta 1 T cells and NK cells express CD45RO and lack expression of CD45RA. Our results strongly suggest that CD45RA and CD45RO are genuine markers for naive and primed lymphocytes that represent distinct differentiation lineages.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832950     DOI: 10.1093/intimm/3.7.691

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

1.  Phenotypical characterization of peripheral blood T cells in patients with coeliac disease: elevation of antigen-primed CD45RO+ T lymphocytes.

Authors:  T O Kerttula; O Hällström; M Mäki
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

2.  Gamma/delta T cells and human skin reactivity to heavy metals.

Authors:  K Nordlind; S Lidén
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

3.  Antigen recognition and activation of ovine gamma delta T cells.

Authors:  C W Evans; B T Lund; I McConnell; R Bujdoso
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

Review 4.  Evolution and function of the TCR Vgamma9 chain repertoire: It's good to be public.

Authors:  C David Pauza; Cristiana Cairo
Journal:  Cell Immunol       Date:  2015-03-04       Impact factor: 4.868

5.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Authors:  J W Gratama; R J Bruin; C H Lamers; R Oosterom; E Braakman; G Stoter; R L Bolhuis
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

6.  Ovine lentivirus is macrophagetropic and does not replicate productively in T lymphocytes.

Authors:  M D Gorrell; M R Brandon; D Sheffer; R J Adams; O Narayan
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model.

Authors:  Gabrielle M Siegers; Tania C Felizardo; A Mark Mathieson; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Armand Keating
Journal:  PLoS One       Date:  2011-02-03       Impact factor: 3.240

8.  Bovine CD2-/NKp46+ cells are fully functional natural killer cells with a high activation status.

Authors:  Preben Boysen; Ingrid Olsen; Ingvild Berg; Siri Kulberg; Grethe M Johansen; Anne K Storset
Journal:  BMC Immunol       Date:  2006-04-27       Impact factor: 3.615

9.  Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis.

Authors:  Sabela Rodríguez-Lorenzo; Lynn van Olst; Carla Rodriguez-Mogeda; Alwin Kamermans; Susanne M A van der Pol; Ernesto Rodríguez; Gijs Kooij; Helga E de Vries
Journal:  Elife       Date:  2022-05-10       Impact factor: 8.713

10.  Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes.

Authors:  M D Roth
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.